Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood

NCT00550667 | Completed DMC

• 1 other identifier: 200705065R
• Study Type: observational
• Target: 1,120
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to establish the psychometric properties of the Adult ADHD Quality of Life Scale (AAQoL) and to validate the diagnosis of adult ADHD by ADHD symptoms, other clinical psychiatric symptoms, neuropsychological functioning, social/family/occupational functioning, and intervention effect.

Conditions

Attention Deficit Disorder With Hyperactivity

Keywords

Attention-deficit hyperactivity disorder; adult; diagnostic validity; neuropsychological functions; social functioning

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

community sample \& clinical sample

You may qualify if:

• Case group:
• Case group I: The cases with childhood ADHD diagnosis diagnosed as ADHD after interview Case group II: The cases with sufficient ADHD symptoms for diagnosis as DSM-IV ADHD at childhood but never assessed or treated for ADHD in childhood
• Control group：The subjects without the DSM-IV-TR diagnosis of ADHD or any major psychiatric disorders.

You may not qualify if:

• Comorbid with DSM-IV-TR diagnosis of pervasive developmental disorder, schizophrenia, schizoaffective disorder, delusional disorder, other psychotic disorder, organic psychosis, schizotypal personality disorder, bipolar affective disorder, severe anxiety disorder(such as OCD, ASD or PTSD) and mental retardation.
• In the major depressive episode, comorbid with severe anxiety disorders or during substance intoxication or withdrawal at the time of evaluation.
• With neurodegenerative disorder, epilepsy, involuntary movement disorder, congenital metabolic disorder, brain tumor, history of severe head trauma, and history of craniotomy.
• With visual or hearing impairments, or motor disability which may influence the process of neuropsychological assessment.

Sponsors & Collaborators

• National Taiwan University Hospital: lead

Study Sites (1)

National Taiwan University Hospital

Taipei, 10002, Taiwan

Location

Related Publications (2)

• Candido RCF, Menezes de Padua CA, Golder S, Junqueira DR. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2021 Jan 18;1(1):CD013011. doi: 10.1002/14651858.CD013011.pub2.

  PMID: 33460048 DERIVED

• Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2013 Oct;16(9):1959-73. doi: 10.1017/S1461145713000357. Epub 2013 May 14.

  PMID: 23672818 DERIVED

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity; Social Adjustment

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior Disorders; Neurodevelopmental Disorders; Mental Disorders; Social Behavior; Behavior

Study Officials

• Susan Shur-Fen Gau, MD, PhD

  Dept of Psychiatry, National Taiwan University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 29, 2007
• First Posted: October 30, 2007
• Study Start: October 1, 2007
• Primary Completion: June 30, 2013
• Study Completion: June 30, 2013
• Last Updated: September 2, 2021

Record last verified: 2021-09

Locations

TW (1)